The Chicago Entrepreneur

Bristol Myers Squibb says Alzheimer’s is the biggest market for new schizophrenia drug

Bristol Myers Squibb plans to release initial late-stage trial data on Cobenfy in Alzheimer’s-related psychosis during the latter part of the year.

Editorial Team

Leave a Reply

Your email address will not be published. Required fields are marked *

Previous post Data Update 1 for 2025: The Draw (and Danger) of Data
Next post Data Update 1 for 2025: The Draw (and Danger) of Data